Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer

Arthralgia Clinical Trial

Official title:

Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05264649
• Other study ID #: 1100903
• Status: Recruiting
• Phase: N/A
• Start date: May 5, 2022
• Est. completion date: March 3, 2023

Study information

• Verified date: November 2022
• Source: Show Chwan Memorial Hospital
• Contact: I-Ting Lee, Bachelor
• Phone: +886-988567228
• Email: iting.lee927[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause, but side effects, such as joint pain, would affect their qualities of life. Chinese herbs or acupuncture provides promising clinical effects and plays an important role on alleviating the side effects of cancer treatment. This clinical trial will evaluate the effect of the acupuncture, Chinese medicine, and the combination of both on joint pain related to aromatase inhibitors among women with early-stage breast cancers.

Description:

Reduce estrogen exposure can lower the risk of breast cancer recurrence. Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause for years. It can increase the survival rate and decrease the chance of recurrence. However, many patients suffered from the side effects of medication, including joint pain, is the main reason for decreasing medication adherence and influencing patients' quality of life. Based on previous phase III clinical trial study, acupuncture may relieve aromatase inhibitor associated joint pain, and experts believe that acupuncture could also be considered as an effective adjuvant treatment. Chinese herbs or acupuncture provides promising clinical effects and plays an important role in alleviating the side effects of cancer treatment. Guizhi-Shaoyao-Zhimu decoction has frequently being prescribed to treat joint pain in traditional Chinese medicine practice. The design of this clinical trial will evaluate the effects of the acupuncture, Chinese medicine, and the combination of both on joint pain related to aromatase inhibitors among women with early-stage breast cancer. The goal of this study was to evaluate the efficacy and safety with regards to utilizing acupuncture and Chinese herbs in treating joint pain related to the usage of aromatase inhibitors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: March 3, 2023
• Est. primary completion date: July 20, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Women with diagnosis of early breast cancer (stages I-III), expressing hormone receptor-positive (ER+, PR+, or both) and took third generation aromatase inhibitors (AIs).

2. Post- or pre-menopausal with the use of a gonadotropin-releasing hormone agonist.

3. Taking AIs for more than 30 days before registration and planned to continue treatment for over 1 year.

4. Have already been recovered from the surgery or chemotherapy.

5. Have a ECOG performance status score of 0 to 1.

6. Joint pain which has developed or worsened since starting AIs therapy. The worst pain item score of Brief Pain Inventory-Short Form (BPI-SF) is at least 3 and above.

7. Have a Eastern Cooperative Oncology Group (ECOG) grading scale for chemotherapy-induced peripheral neuropathy score of 1 to 2.

8. The patient could cooperate the intervention and sign the informed consent.

Exclusion Criteria:

1. Had received acupuncture treatment for joint pain would be excluded, but patients with acupuncture treatment for less than 2 times due to other reasons could be included.

2. Had a history of fractures or underwent surgery on the knee or hand joints in the past six months.

3. Had severe bleeding disorders. The platelet counts are below 50,000 per µl.

4. Cognitive disorders (included dementia).

5. Lymphedema after breast cancer surgery.

Related Conditions & MeSH terms

• Arthralgia

Intervention

Device:
• acupuncture
The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes "De Qi" reported by patients, needles were restimulated manually and removed after an additional 10 minutes.

Drug:
• Guizhi-Shaoyao-Zhimu decoction
The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.

Locations

Country	Name	City	State
Taiwan	ShowChwanMH	Changhua

Sponsors (1)

Lead Sponsor	Collaborator
Show Chwan Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brief Pain Inventory-Worst Pain Item (BFI-WP)	a 0- to 10-point scale (0 [no pain] to 10 [pain as bad as you can imagine)	Change from baseline at 6 weeks
Secondary	Brief Pain Inventory - Short Form (BPI-SF)	The Brief Pain Inventory-Short Form (BPI-SF) was used to evaluate the worst pain, pain severity, and pain- related interference scores. (0 [no pain] to 10 [pain as bad as you can imagine)	Change from baseline at 6 weeks
Secondary	Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)	The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used in the evaluation of pain (score range, 0-20), stiffness (score range, 0-8), physical function of lower limb (score range, 0-68).	Change from baseline at 6 weeks
Secondary	Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH)	Affections of the Hands (M-SACRAH) was used in the evaluation of pain, stiffness, physical function of upper limb.	Change from baseline at 6 weeks
Secondary	Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)	The Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) measured physical and functional well- being and endocrine symptoms (score range, 0-128)	Change from baseline at 6 weeks